115 results
10-K
2022 FY
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
in women undergoing in-vitro fertilization (“IVF”).
We in-licensed nolasiban from Ares Trading S.A., an affiliate of Merck Serono (“Merck Serono … the following:
Continue to advance the development program for nolasiban for the improvement of clinical pregnancy and live birth rates in women
6-K
EX-99.1
OBSVF
ObsEva SA
14 Dec 22
ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filing
7:15am
reproductive health and pregnancy. ObsEva has established a development program focused on improving clinical pregnancy and live birth rates in women undergoing
6-K
EX-99.1
OBSVF
ObsEva SA
9 Dec 22
ObsEva To Increase Issued Share Capital by Creating Additional Treasury Shares
7:09am
on improving clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva is listed on the Nasdaq Global Select Market
F-3
OBSVF
ObsEva SA
9 Dec 22
Shelf registration (foreign)
7:06am
medical needs.
Nolasiban is a novel, oral oxytocin receptor antagonist being developed to improve clinical pregnancy and live birth rates in women
6-K
EX-99.2
OBSVF
ObsEva SA
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
on improving clinical pregnancy and live birth rates in women undergoing in vitro fertilization.
On July 27, 2022, we announced plans to initiate a corporate … for the improvement of pregnancy and birth rates in women undergoing embryo transfer following in-vitro fertilization
In January 2020, we and Hangzhou YuYuan
6-K
EX-99.3
tgiyoyl is03a86
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
6-K
EX-99.2
qsh1g9kk
22 Nov 22
Consent and Amendment Agreement
7:10am
6-K
EX-99.1
d2mnqfgi
26 Oct 22
ObsEva Announces Progress on Cost Reduction Initiatives and Stay of
5:11pm
6-K
EX-99.1
j7jk7 8ghqmtov15
13 Oct 22
ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China
7:13am
6-K
EX-99.1
azmaz
13 Sep 22
ObsEva Announces Progress on Restructuring Initiatives
9:13am
6-K
EX-99.1
1m1fvtyce0
22 Aug 22
ObsEva Receives Nasdaq Non-Compliance Notice
6:08am
6-K
EX-99.2
zcws32 jfluxd
17 Aug 22
Index to Unaudited Condensed Consolidated Financial Statements
4:01pm
6-K
EX-99.3
7wp2iaj36mxgoiu1
17 Aug 22
Index to Unaudited Condensed Consolidated Financial Statements
4:01pm
6-K
EX-99.1
5oxzsoclaz
1 Aug 22
ObsEva Announces $31 million Debt Retirement and $11 million Debt Refinancing
7:21am
6-K
EX-99.1
q64 p1kl77f94o39gpyi
29 Jul 22
ObsEva Announces Management Change
7:06am
6-K
EX-99.2
00nk 58j1i
27 Jul 22
ObsEva Announces Corporate Updates
7:03am
6-K
EX-99.1
x37b lj9n97
27 Jul 22
ObsEva Announces Corporate Updates
7:03am
6-K
EX-99.1
o3f3xellp4 rmg
28 Jun 22
ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
4:13pm
6-K
EX-99.1
iuakn1 knjz80c2pvum3
17 Jun 22
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
7:05am
6-K
EX-99.3
wd43hdl16ml
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am